Natco Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

Natco Pharma today announced submission of Abbreviated New Drug Application (ANDA) with USFDA  for Risdiplam for Oral Solution.

NATCO believes it is amongst one of the first two companies to have filed a substantially-complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances. NATCO has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc.

EVRYSDI® has recorded sales of USD 571 million in the US market for the year 2023.

Risdiplam for Oral Solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Powered by Capital Market - Live News

The ANDA is a generic version of Evrysdi (Risdiplam) for oral solution by Genentech Inc.

Risdiplam for oral solution is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

The drug maker believes it is amongst the first two companies to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of shared marketing exclusivity at the time of potential launch of the generic product under certain circumstances.

The company has been named as one of the defendants in a lawsuit filed in the United States District Court for the District of New Jersey by Genentech, Inc., Hoffmann-La Roche Inc., and PTC Therapeutics, Inc.

Evrysdi has recorded sales of $571 million in the US market for the year 2023.

Natco Pharma is engaged in the business of pharmaceuticals which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The company has manufacturing facilities in India which caters to both domestic and international markets including regulated markets like the United States of America and Europe.

The company’s consolidated net profit surged 83.55% to Rs 677.30 crore on a 32.93% increase in revenue from operations to Rs 1,371.1 crore in Q2 FY25 over Q2 FY24.

The scrip rose 0.64% to currently trade at Rs 1,374.95 on the BSE.

Powered by Capital Market - Live News

Natco Pharma has fixed 27 November 2024 as record date for taking on record of its shareholders eligible for the purpose of payment of second interim dividend. The dividend will be paid from 04 December 2024.

Powered by Capital Market - Live News

Natco Pharma Ltd dropped for a fifth straight session today. The stock is quoting at Rs 1376.75, down 1.01% on the day as on 12:59 IST on the NSE. The benchmark NIFTY is down around 0.94% on the day, quoting at 23659.1. The Sensex is at 78018.99, down 0.83%.Natco Pharma Ltd has eased around 3.09% in last one month.Meanwhile, Nifty Pharma index of which Natco Pharma Ltd is a constituent, has eased around 7.95% in last one month and is currently quoting at 22151.6, down 1.6% on the day. The volume in the stock stood at 15.6 lakh shares today, compared to the daily average of 4.86 lakh shares in last one month.

The PE of the stock is 16.23 based on TTM earnings ending June 24.

Powered by Capital Market - Live News